


Please amend the Claims as follows:

1. (Currently amended) The use of A method of treating attention deficit disorders comprising the step of administering a medicament comprising galantamine or a derivative thereof of formula I:



wherein the broken line represents an optionally present double bond between carbon atoms 3 and 4, each R_1 is independently selected from hydrogen, hydroxyl, straight or branched chain alkyl, hydroxyalkyl, carboxyalkyl amino, alkylamino, acyl, lower alkanoyl, cyano, sulfhydryl, C_{1-6} alkoxy, alkylthio, aryloxy, arylthio, R_3 -substituted aryloxy, R_3 -substituted arylthio, aralkoxy, an optionally R_3 -substituted aliphatic or aryl carbamyl group, aralkylthio, R_3 -substituted aralkoxy, R_3 -substituted aralkylthio, aryloxymethyl, R_3 -substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, R_3 -substituted benzoyloxy, aryloxycarbonyl and R_3 -substituted aryloxycarbonyl,

R_2 is selected from hydrogen, straight or branched chain C_{1-6} alkyl, alkenyl or alkaryl group, optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroaryl-alkyl, aryl, arylalkyl, cyano, amyl, aroyl, cycloalkylmethyl, allyl, phenyl, R_3 -substituted phenyl, alkylphenyl, R_3 -substituted alkylphenyl, heterocyclyl selected from α - or β -furyl, α - or β -thienyl, thenyl, pyridyl, pyrazinyl, and pyrimidyl, alkyl-heterocyclyl or

R' -substituted heterocyclyl, where R' is alkyl or alkoxy,

each R_3 is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, hydroxyalkyl, aryl, aralkyl, alkoxy, mercaptoalkyl, aryloxy, thiaryloxy, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkaryl amino, fluoro, chloro, bromo, iodo, and trifluoromethyl,

each R_4 is independently selected from hydrogen, halo, trifluoromethyl or C_{1-4} -alkyl,

each R_5 is independently selected from hydrogen or hydroxymethyl,

R_6 is hydrogen or C_{1-6} alkyl, ~~or when R_4 at carbon atom 2 is hydroxyl, R_6 may be a moiety of formula I wherein R_6 is hydrogen and R_4 is a linking bond; or~~


R_1 at carbon atom 2 and R_6 may jointly form semicarbazone,

X is oxygen or NR_3 ,

Y is nitrogen or phosphorus,

and methylenedioxy derivatives thereof and pharmaceutically acceptable acid addition salts thereof in the manufacture of a medicament for combatting attention deficit disorders wherein said galantamine derivative is an acetylcholinesterase inhibitor that is active selectively at nicotinic receptor sites and is capable of crossing the blood-brain barrier.

2. (Currently amended) The use of A method of treating attention deficit disorders comprising the step of administering a medicament comprising galantamine or a derivative thereof of formula II



wherein R^1 and R^2 which may be the same or different each represents a hydrogen atom or an acyl group, such as a lower alkanoyl group, e.g. an acetyl group or a straight-chained or branched alkyl group, e.g. methyl, ethyl, propyl, or isopropyl;

R^3 is a straight or branched chain alkyl, alkenyl or alkaryl group which is optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroarylalkyl, aroyl, aroylalkyl or cyano group; and

R^4 represents a hydrogen or a halogen atom attached to at least one of the ring carbons of the tetracyclic skeleton,

and pharmaceutically acceptable salts thereof, such as a hydrobromide, hydrochloride, methylsulphate or methiodide in the manufacture of a medicament for combatting attention deficit disorders. wherein said galantamine derivative is an acetylcholinesterase inhibitor that is active selectively at nicotinic receptor sites and is capable of crossing the blood-brain barrier.

3. (Currently amended) The use of A method of treating attention deficit disorders comprising the step of administering a medicament comprising galantamine or a salt thereof. in the manufacture of a medicament for combating attention deficit disorders

4. (Currently amended) The use is claimed in method of any one of claims 1 to 3, wherein the disorder is attention deficit hyperactivity disorder.

5. (Currently amended) The ~~use as claimed in~~ method of any one of claims 1 to 3, wherein the disorder is a hyperkinetic disorder.

6. Cancelled

7. Cancelled